These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36675069)
1. DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning. Oberemok VV; Andreeva OA; Alieva EE Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675069 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668 [TBL] [Abstract][Full Text] [Related]
3. Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond. Oberemok VV; Andreeva OA; Laikova KV; Novikov IA; Kubyshkin AV Inflamm Res; 2022 Aug; 71(7-8):729-739. PubMed ID: 35523969 [TBL] [Abstract][Full Text] [Related]
4. Human Defensins from Antivirals to Vaccine Adjuvants: Rediscovery of the Innate Immunity Arsenal. Zupin L; Crovella S Protein Pept Lett; 2022; 29(2):121-124. PubMed ID: 34823454 [TBL] [Abstract][Full Text] [Related]
5. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406 [TBL] [Abstract][Full Text] [Related]
7. The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2. Sohrab SS; Suhail M; Kamal MA; Ahmad F; Azhar EI Curr Pharm Des; 2020; 26(41):5286-5292. PubMed ID: 32954998 [TBL] [Abstract][Full Text] [Related]
8. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Gupta T; Gupta SK Int Immunopharmacol; 2020 Sep; 86():106717. PubMed ID: 32585611 [TBL] [Abstract][Full Text] [Related]
9. Nucleoside Inhibitors of Coronaviruses. Zenchenko AA; Drenichev MS; Mikhailov SN Curr Med Chem; 2021; 28(26):5284-5310. PubMed ID: 33563148 [TBL] [Abstract][Full Text] [Related]
10. Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2. Hussein M; Andrade Dos Ramos Z; Vink MA; Kroon P; Yu Z; Enjuanes L; Zuñiga S; Berkhout B; Herrera-Carrillo E Viruses; 2023 Mar; 15(3):. PubMed ID: 36992394 [TBL] [Abstract][Full Text] [Related]
11. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758 [TBL] [Abstract][Full Text] [Related]
12. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. Tomalka JA; Suthar MS; Deeks SG; Sekaly RP Nat Immunol; 2022 Mar; 23(3):360-370. PubMed ID: 35210622 [TBL] [Abstract][Full Text] [Related]
13. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. Krishna G; Pillai VS; Veettil MV Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174 [TBL] [Abstract][Full Text] [Related]
14. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro. Lee G; Budhathoki S; Lee GY; Oh KJ; Ham YK; Kim YJ; Lim YR; Hoang PT; Lee Y; Lim SW; Kim JM; Cho S; Kim TH; Song JW; Lee S; Kim WK Viruses; 2021 Apr; 13(4):. PubMed ID: 33918914 [TBL] [Abstract][Full Text] [Related]
15. Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. Akram F; Haq IU; Aqeel A; Ahmed Z; Shah FI; Nawaz A; Zafar J; Sattar R J Virol Methods; 2022 Feb; 300():114375. PubMed ID: 34838536 [TBL] [Abstract][Full Text] [Related]
16. Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options. Sohrab SS; Suhail M; Kamal MA; Azhar EI Curr Pharm Des; 2021; 27(32):3444-3453. PubMed ID: 33302852 [TBL] [Abstract][Full Text] [Related]
17. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293 [TBL] [Abstract][Full Text] [Related]
18. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2. Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987 [TBL] [Abstract][Full Text] [Related]